#EULAR2025 Abstr#OP0202 Phase 1/2 of Resel-cel, a 4-1BB-containing human CD19-CAR T cell (weight-based 1 x infusion) reported efficacy in 8 patients (#SLE and LN) at WK28. 2 x Grade 1 CRS & 1 x Grade 4 ICANS. 1 x HLH, not attributed to SLE flare. Need longterm data @RheumNow https://t.co/COCKlqw687

• https://x.com/Yuz6Yusof/status/1933397540470182033/photo/1

#Enpatoran a #TLRi in Phase2 #SLE #RCT -previous data + small #cutaneous #lupus study various doses &PBO approx 25/group Interesting data - seems to ⬇️#IFN + endpoints 👀 for more to come! Safe so far #EULAR2025 @RheumNow @eular_org LateBreaking I https://t.co/OtgiasBerX

• https://x.com/Janetbirdope/status/1933865825825374650/photo/1
• https://x.com/Janetbirdope/status/1933865825825374650/photo/1
• https://x.com/Janetbirdope/status/1933865825825374650/photo/1

Key summary slide of research in the use of CD19 CAR T cells in rheumatology indications Dinesh Khanna @RheumNow #EULAR2025 https://t.co/CoFHqaE1L1

• https://x.com/synovialjoints/status/1933786800495210968/photo/1

Which CAR-based strategies would you consider to treat severe refractory #SLE based on data presented at #EULAR2025? @RheumNow

URAT1 inhibitors look like the way to go in Gout! Presented in multiple abstracts at #EULAR2025 Pozdeutinurad Ph2 long term safety data chronic gouty arthritis + tophi OP0300 Ph3 RCT of Ruzinurad in hyperuricemia/primary gout OP0302 Ph 2b RCT of SAP-001 Refractory Gout +/-

Deucravacitinib, the first oral TYK2 inhibitor, delivers in PsA: ✅ ACR20: 54% vs 34% (placebo) ✅ Skin, joints, fatigue, QoL 📉 Post hoc: less radiographic progression No new safety signals at W16. LB0001 @RheumNow #EULAR2025

from Rituximab to BiTES to CAR T, always looking for deeper B cell depletion Safety data from CC312 CD19/CD3/CD28, a triple engager in refractory moderate-to-severe SLE So far so good but how far do we need to go? #EULAR2025 @RheumNow LB0007

🌳#WILLOW: TLR7/8 inhibition with enpatoran led to greater BICLA response, IFN signature reduction & skin improvement (CLASI-50/70) in active SLE vs placebo at 24wks. Most benefit seen in pts with high IFN-GS or GC use. Good tolerability. @RheumNow #EULAR2025 #LB0004

Nerandomilast: the new & improved nintedanib. Does it work for our rheum pts? Autoimmune subgroup of FIBRONEER-ILD (NEJM last month) - mortality benefit vs placebo (this is new) - well tolerated (minimal increase in diarrhoea vs placebo) One to watch #EULAR2025 LB0003 @RheumNow https://t.co/u8fIy7kkKW

• https://x.com/drdavidliew/status/1933816210619076931/photo/1
• https://x.com/drdavidliew/status/1933816210619076931/photo/1
• https://x.com/drdavidliew/status/1933816210619076931/photo/1

FIBRONEER-ILD Ph3 PD4B inhibitor Nerandomilast 1100+ pts, 320+ w/ SARD-ILD wk52 FVC relative reduction of decline 9 mg bid 43% 18 mg bid 39% vs. PBO HR 0.56 time to first acute exacerbation of ILD, hospitalisation for resp cause or death in higher dose group 11% https://t.co/CeXWB2GlOe

• https://x.com/AurelieRheumo/status/1933816838330122591/photo/1

#EULAR2025 Abstr#LB0004 Phase 2 RCT of first-in-class, Enpatoran, TLR7/8-i in active #SLE despite SOC (Cohort B) reported nominal improvement in BICLA but no dose-dependent response. Greater effects seen on active CLE, high IFN-GS or high dose GC. No major safety signal @RheumNow https://t.co/aX4ier0rAy

• https://x.com/Yuz6Yusof/status/1933822271946170534/photo/1

Enpatoran (TLR7/8 inhibitor) in SLE & CLE - helps skin, others? - suppresses interferon lowest dose was highest response though (upsetting primary endpoint) Promising, watch for the ph3 No photos allowed, but official slides: https://t.co/1yX6XrYvKH #EULAR2025 LB0004 @RheumNow

• Randomised, Placebo-Controlled Phase II Study of Oral Enpatoran, a First-in-Cla…

💉Early results from a dose-escalation trial of novel CD19xCD3xCD28 trispecific antibody (CC312) in refractory #SLE show no ICANS or ≥G2 CRS, rapid B cell depletion & 100% SRI-4 response (n=5). @RheumNow #EULAR2025 #LB0007 #CART

🦵🏻SAP-001, a novel uricosuric targeting a non-URAT1 renal transporter, lowered sUA <6 mg/dL in up to 79% of patients with refractory #gout on b/g xanthine oxidase inhibitor. >50% on 60 mg/day reached sUA <3 mg/dL. 💊Potential new oral ULT option. @RheumNow #EULAR2025 #LB0008 https://t.co/dfY1V5sHSh

• https://x.com/DrMiniDey/status/1933827756070178890/photo/1

Results from open label extension of BE-OPTIMAL: -Bimekizumab in bDMARD naïve pts showed sustained efficacy after 1y until 3y. -No significant major tolerability issues or major SE. abstract #POS1294 #EULAR2025 @RheumNow https://t.co/VAEiciCR1z

• https://x.com/AdelaCastro222/status/1933834754052247622/photo/1